News & Updates

Show Multimedia Only

Dabigatran or warfarin: Choice does not matter in GIRAF

16 Dec 2021 by

The choice of oral anticoagulant does not appear to influence the outcome in terms of preserving cognitive function in older patients with atrial fibrillation (AF), the GIRAF* study has shown.

16 Dec 2021

Ustekinumab yields high remission in Crohn’s disease, even for fistulizing disease

15 Dec 2021 by

Treatment with the anti-interleukin (IL)-12/-23 monoclonal antibody ustekinumab yields a high rate of clinical remission in patients with moderate-to-severe Crohn’s disease (CD) in the real-world setting, according to a study presented at AIBD 2021.

15 Dec 2021

Entecavir prevents HBV reactivation in individuals on DAA for HCV/HBV dual infection

15 Dec 2021

For patients undergoing direct acting antiviral (DAA) therapy for hepatitis C virus (HCV)/hepatitis B virus (HBV) dual infection, cotreatment with entecavir helps avert reactivation of HBV, as shown in a study.

15 Dec 2021

Study offers clues on which patients may safely stop HBV therapy

15 Dec 2021 by

Think twice before withdrawing HBV treatment. Not all patients can safely discontinue nucleos(t)ide analogue (NA) therapy as shown in the retrospective RETRACT-B study of patients from Europe, North America, and Asia.

15 Dec 2021

DOACs tied to lower risk of delayed ICH than older blood thinning meds

14 Dec 2021 by

Patients on older antiplatelet or anticoagulant agents who sustain head trauma may be at an increased risk of delayed post-traumatic intracranial haemorrhage (ICH) than those on direct oral anticoagulants (DOACs), according to a retrospective study presented at RSNA 2021.

14 Dec 2021

Probiotic use in IBD may cloud the mind

14 Dec 2021 by

Patients with inflammatory bowel disease (IBD) who consume probiotics can develop brain fog, especially men and those who are Caucasian, as suggested in a study.

14 Dec 2021

Antidepressant therapy: To continue or not?

14 Dec 2021 by

In individuals who had been on antidepressant therapy for at least 9 months but felt well enough to consider discontinuing, the risk of relapse of depression was greater among those who stopped vs those who carried on with their current regimen, the ANTLER* trial has shown.

14 Dec 2021

Is prior allergy a deal-breaker for COVID-19 vacc?

13 Dec 2021 by

A large prospective, observational study has suggested that while individuals with a history of high-risk allergy may have an increased risk of allergic reactions following receipt of a messenger RNA (mRNA) COVID-19 vaccine, they are still able to receive both vaccine doses.

13 Dec 2021

Real-world data capture low use of DOACs among children

13 Dec 2021 by

Use of direct oral anticoagulants (DOACs) appears to be limited in paediatric clinical practice, with heparins being the most prescribed, followed by warfarin.

13 Dec 2021

Opioid medication linked to patients’ familiarity, perceptions of efficacy

13 Dec 2021

Use of opioid among adults with knee and/or hip osteoarthritis (OA) often leads to being familiar with the treatment and believing that the medication is beneficial and low-risk, reveals a recent study.

13 Dec 2021

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Dabigatran or warfarin: Choice does not matter in GIRAF

Ustekinumab yields high remission in Crohn’s disease, even for fistulizing disease

Entecavir prevents HBV reactivation in individuals on DAA for HCV/HBV dual infection

Study offers clues on which patients may safely stop HBV therapy

DOACs tied to lower risk of delayed ICH than older blood thinning meds

Probiotic use in IBD may cloud the mind

Antidepressant therapy: To continue or not?

Is prior allergy a deal-breaker for COVID-19 vacc?

Real-world data capture low use of DOACs among children

Opioid medication linked to patients’ familiarity, perceptions of efficacy